Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback